---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-069258"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:26:21.066965+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acura receives two $100K loans from AD Pharma; warns of possible operations halt if no further financing by Aug 2025

## Summary
- Principal on secured note rises to $8,394,279 with ~$740K accrued interest; interest rate 5.25%.
- Loans of $100K each on July 3 and July 18, 2025 from Abuse Deterrent Pharma, LLC (AD Pharma).
- Without additional financing by early August 2025, company may furlough employees or seek bankruptcy protection.
- AD Pharma owns ~65% of outstanding common stock (excludes warrant for 10M shares).
- Funds used for day-to-day operations; no assurance of further financing.

## SEC filing metadata
- accession: 0001104659-25-069258
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/0001104659-25-069258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/tm2521314d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-069258
- JSON: https://secwatch.observer/filing/0001104659-25-069258.json
- Plain text: https://secwatch.observer/filing/0001104659-25-069258.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $8,394,279 with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: $8,394,279
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On each of July 3, 2025 and July 18, 2025, we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma"). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $8,394,279 with accrued interest of approximately $740,000 as of July 21 2025, and bears interest at 5.25% ("Note").
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/0001104659-25-069258-index.htm
- M&A Transactions
  ACURA PHARMACEUTICALS, INC completed an acquisition involving Abuse Deterrent Pharma, LLC.
  - Action: acquisition
  - Counterparty: Abuse Deterrent Pharma, LLC
  source text: Item 2.01 – Completion of Acquisition or Disposition of Assets The contents of all Items 1.01 are incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/0001104659-25-069258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.